The roles of various new N-heterocyclic moieties against different human cancer cell lines are discussed. The SAR of the newly synthesized derivative are illustrated in figures. Novel fused heterocyclic moieties and new complexes showing significant anticancer properties are also presented. Interactions of some newly synthesized compounds with the receptors is confirmed by docking studies.